Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23195598 | 1.00 | GRM2 (0.34) | GRM2CFTRHDAC2HDAC1CYP3A4 | |
| SCHEMBL23905460 | 0.92 | CFTR (0.34) | GRM2CFTRHDAC2HDAC1CYP3A4 | |
| SCHEMBL23196149 | 0.89 | GRM2 (0.38) | GRM2CFTRHDAC2HDAC1PDE3B | |
| SCHEMBL23196147 | 0.89 | GRM2 (0.38) | GRM2CFTRHDAC2HDAC1PDE3B | |
| SCHEMBL23196044 | 0.85 | GRM2 (0.35) | GRM2CFTRHDAC2HDAC1PDE3B | |
| SCHEMBL23196017 | 0.85 | — | — | |
| SCHEMBL24985735 | 0.85 | GRM2 (0.38) | GRM2CFTRHDAC2HDAC1PDE3B | |
| SCHEMBL23195889 | 0.85 | GRM2 (0.38) | GRM2CFTRHDAC2HDAC1PDE3B | |
| SCHEMBL31412382 | 0.85 | GRM2 (0.38) | GRM2CFTRHDAC2HDAC1PDE3B | |
| SCHEMBL24984659 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | GRM2 4163/4885CFTR 283/4885HDAC2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.